Jenny Fox, MD
Hematology & Oncology · Boulder, CONPI 1295719904
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,221 with a category attached, or 90.1%. Athenex Pharmaceutical Division, LLC accounts for 90.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $2,111 and has fallen 96.2% since, to $79 in 2022. That places this record below the midpoint for hematology & oncology clinicians in CO, where the typical reported total is $1,826.
Across 8 payments — averaging $277.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Athenex Pharmaceutical Division, LLC$2K
- Seagen Inc.$99
- Myriad Genetic Laboratories, Inc.$66
- Novartis$31
- Bristol Myers Squibb$13
- Gilead$12
Across 507 payments — averaging $9257.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.8M
- Seagen Inc.$1.5M
- AstraZeneca$1M
- Pfizer$210K
- Genentech, Inc.$147K
- Veru Inc.$29K
What the payments were for
- Speaking & faculty fees$2,00090%
- Food & beverage$1105%
- Education$1115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Athenex Pharmaceutical Division, LLC | 1 | $2,000 |
| Seagen Inc. | 1 | $99 |
| Myriad Genetic Laboratories, Inc. | 3 | $66 |
| Novartis | 1 | $31 |
| Bristol Myers Squibb | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$2,221 in reported general payments places this provider in the 50th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 16 | $244,088 |
| KisqaliRibociclib Succinate | 13 | $228,106 |
| RevlimidLenalidomide | 14 | $227,198 |
| Exemestane | 23 | $2,973 |
| Anastrozole | 153 | $1,998 |
| Tamoxifen Citrate | 70 | $1,520 |
| Letrozole | 62 | $1,200 |
| Gabapentin | 18 | $576 |
| Hydroxyurea | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $31 | $228,10613 claims |
| Bristol Myers SquibbRevlimid | $13 | $227,19814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Boulder
- David AndorskyBoulder$39K
- Leslie BusbyBoulder$17K
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.